iOnctura

📍 Geneve, Switzerland🗓 Founded 2017👥 23 employees💰 Last funded Apr 2023
Biotechnology Research🌐 ionctura.com
Website LinkedIn
iOnctura is a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways such as cellular proliferation; escape from immune detection; and drug resistance. iOnctura’s pioneering approach to drug development is expected to offer significant clinical benefits over the traditional approach of targeting a single pathway alone. iOnctura has progressed two therapeutic candidates into mid-stage clinical development: IOA-244, a highly selective allosteric inhibitor of PI3Kδ to treat Treg-driven tumors; and IOA-289, a highly selective, non-competitive autotaxin (ATX) inhibitor to treat cancer associated fibroblast (CAF) driven tumors. iOnctura is backed by specialist institutional investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health Fund. For more information, please visit www.ionctura.com
5
Total investors
2
Early stage
2
Mid stage
1
Late stage
2017
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Switzerland
3
Netherlands
2
Investor activity2017–2023 · investors recorded per year
201722020220231
Recent (last 2y)Earlier
Frequently asked questions
Who invested in iOnctura?
iOnctura has 5 investors on record on gritt.io, including 2 early-stage backers, 2 mid-stage and 1 late-stage investors.
When did iOnctura last raise funding?
The most recent investment in iOnctura recorded on gritt.io was in April 2023.
When was iOnctura founded?
iOnctura was founded in 2017.
What industry is iOnctura in?
iOnctura operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is iOnctura based?
iOnctura is headquartered in Geneve, Switzerland.